| Not Yet Recruiting | A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) NCT07465757 | Puma Biotechnology, Inc. | Phase 2 |
| Recruiting | Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stag NCT07339059 | Bindu R Potugari | Phase 2 |
| Recruiting | Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherap NCT07476287 | Pfizer | Phase 2 |
| Not Yet Recruiting | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, i NCT07488923 | Moonlight Bio, Inc | Phase 1 |
| Not Yet Recruiting | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer NCT07153055 | Misty Shields | Phase 1 / Phase 2 |
| Not Yet Recruiting | DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizum NCT07472517 | Boehringer Ingelheim | Phase 3 |
| Recruiting | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors NCT07517198 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expr NCT07278479 | Molecular Partners AG | Phase 1 / Phase 2 |
| Recruiting | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871 | Radiopharm Theranostics, Ltd | Phase 1 / Phase 2 |
| Recruiting | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) NCT07480213 | Beijing Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consol NCT07358676 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer NCT07149363 | Alliance Foundation Trials, LLC. | Phase 2 |
| Recruiting | A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC NCT07434518 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Recruiting | Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab NCT07510724 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Recruiting | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemothera NCT07226999 | Pfizer | Phase 2 / Phase 3 |
| Recruiting | TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC NCT07246304 | TCRCure Biopharma Ltd. | EARLY_Phase 1 |
| Not Yet Recruiting | Penfluridol for Relapsed/Refractory Small Cell Cancers NCT07206563 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stag NCT07103408 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subject NCT07075627 | Addario Lung Cancer Medical Institute | — |
| Enrolling By Invitation | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Product NCT06885424 | A2 Biotherapeutics Inc. | — |
| Recruiting | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors NCT07030257 | Tasca Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer NCT07106528 | Peking Union Medical College Hospital | Phase 2 / Phase 3 |
| Not Yet Recruiting | Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer NCT07076836 | West China Hospital | N/A |
| Recruiting | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer NCT07508852 | Peking University First Hospital | Phase 1 / Phase 2 |
| Recruiting | Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Re NCT06736418 | Abdera Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC NCT06745323 | Amgen | Phase 2 |
| Enrolling By Invitation | Sarcopenia and Cachexia in Patients With Lung Cancer NCT06730685 | Zealand University Hospital | — |
| Recruiting | Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial NCT06485544 | Tang-Du Hospital | Phase 2 |
| Recruiting | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962 | Radiopharm Theranostics, Ltd | EARLY_Phase 1 |
| Recruiting | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686 | Phanes Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer NCT05740566 | Amgen | Phase 3 |
| Recruiting | JAB-2485 Activity in Adult Patients With Advanced Solid Tumors NCT05490472 | Jacobio Pharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC NCT05158491 | JenKem Technology Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC NCT05027100 | Haibo Zhang | N/A |
| Completed | Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) NCT04727853 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 | PMV Pharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. NCT04285866 | Fundación GECP | — |
| Completed | Prospective Clinicogenomic Program NCT04180176 | Genentech, Inc. | Phase 4 |
| Completed | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors NCT03811652 | MedImmune LLC | Phase 1 |
| Completed | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With A NCT03708328 | Hoffmann-La Roche | Phase 1 |
| Completed | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies NCT03538028 | Incyte Biosciences International Sàrl | Phase 1 |
| Recruiting | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or NCT03556228 | VM Oncology, LLC | Phase 1 / Phase 2 |
| Recruiting | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and NCT03460977 | Pfizer | Phase 1 |
| Completed | Pembrolizumab in Untreated Extensive SCLC NCT02580994 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients Wi NCT03505515 | Bristol-Myers Squibb | — |
| Withdrawn | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas NCT02030184 | University of Maryland, Baltimore | Phase 1 / Phase 2 |
| Completed | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Parti NCT03066778 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) NCT02934503 | NYU Langone Health | Phase 2 |
| Unknown | Study in Patients With SCLC of Veliparib in Combination With Topotecan NCT03227016 | Central European Society for Anticancer Drug Research | Phase 1 |
| Completed | Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer NCT02769832 | Muhammad Furqan | Phase 2 |
| Terminated | Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer NCT02748889 | Giuseppe Giaccone | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor NCT02069158 | Cristiana Sessa | Phase 1 |
| Terminated | A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Plat NCT01904253 | Taiho Oncology, Inc. | Phase 2 |
| Withdrawn | Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC) NCT01210131 | Maastricht Radiation Oncology | N/A |
| Terminated | Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors NCT01719861 | Joel Neal | Phase 2 |